ReviewBiomedicines2023
The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- A multidisciplinary algorithmic approach to psoriasis with cardiovascular comorbidities: integrating dermatology, internal medicine, cardiology and primary care.Internal medicine journal · 2026Article
- [Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis].Wiener klinische Wochenschrift · 2026Article
- Mechanistic insights into psoriasis and type 2 diabetes mellitus comorbidity - Implications for treatment: A review.Biomolecules & biomedicine · 2026Review
- The Heart of Psoriasis: Cardiovascular Alterations and Common Inflammatory Mechanisms.Current cardiology reviews · 2026Review
- Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.Dermatology and therapy · 2025Article
- Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.JAMA dermatology · 2025Article
- Article
- Review
- Exploring endothelial dysfunction in major rheumatic diseases: current trends and future directions.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation.Metabolites · 2025Review
- Therapeutic Advancements in Psoriasis and Psoriatic Arthritis.Journal of clinical medicine · 2025Review
- Impact of topical and systemic therapy on carotid-intima media thickness in psoriasis.Archives of dermatological research · 2025Article
- Association between aortic calcification and cytokine levels in patients with peripheral artery disease.Clinical and translational science · 2024Article
- Article
- Arterial function is preserved in successfully treated patients with psoriasis vulgaris.Science progressArticle
- Hidradenitis Suppurativa: Beyond Skin Concerns to Focus on Cardiovascular Considerations.The Journal of clinical and aesthetic dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence considers psoriasis a systemic inflammatory disorder that is associated with comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. Although the precise pathogenetic links between psoriasis and atherosclerosis warrants further investigation, it is believed that chronic systemic inflammation along with the T helper (Th)-1 and Th17 polarization are associated with endothelial dysfunction and subsequent acceleration of atherosclerosis. Considering the above, several studies have evaluated if optimal control of the inflammation in psoriasis by inhibiting interleukins targeting the Interleukin (IL)-23/Th17 axis could subsequently reduce the atherosclerotic process during anti-psoriatic treatment by using a variety of surrogate markers of subclinical atherosclerosis. This systematic review summarizes current knowledge on the pathogenetic mechanisms and diagnostic evaluation of atherosclerosis in the context of psoriasis and provides a systematic review of the literature on the impact of treatment with biologics targeting the IL-23/Th17 axis on subclinical atherosclerosis in patients with plaque psoriasis and/or psoriatic arthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.